1nn3 Citations

Structures of human thymidylate kinase in complex with prodrugs: implications for the structure-based design of novel compounds.

Biochemistry 42 2568-77 (2003)
Related entries: 1nmx, 1nmy, 1nmz, 1nn0, 1nn1, 1nn5

Cited: 20 times
EuropePMC logo PMID: 12614151

Abstract

Nucleoside analogue prodrugs are dependent on efficient intracellular stepwise phosphorylation to their triphosphate form to become therapeutically active. In many cases it is this activation pathway that largely determines the efficacy of the drug. To gain further understanding of the determinants for efficient conversion by the enzyme thymidylate kinase (TMPK) of clinically important thymidine monophosphate analogues to the corresponding diphosphates, we solved the crystal structures of the enzyme, with either ADP or the ATP analogue AppNHp at the phosphoryl donor site, in complex with TMP, AZTMP (previous work), NH2TMP, d4TMP, ddTMP, and FLTMP (this work) at the phosphoryl acceptor site. In conjunction with steady-state kinetic data, our structures shed light on the effect of 3'-substitutions in the nucleoside monophosphate (NMP) sugar moiety on the catalytic rate. We observe a direct correlation between the rate of phosphorylation of an NMP and its ability to induce a closing of the enzyme's phosphate-binding loop (P-loop). Our results show the drastic effects that slight modifications of the substrates exert on the enzyme's conformation and, hence, activity and suggest the type of substitutions that are compatible with efficient phosphorylation by TMPK.

Articles citing this publication (20)

  1. Metabolism of 3'-deoxy-3'-[F-18]fluorothymidine in proliferating A549 cells: validations for positron emission tomography. Grierson JR, Schwartz JL, Muzi M, Jordan R, Krohn KA. Nucl Med Biol 31 829-837 (2004)
  2. Substrate-induced conformational changes in human UMP/CMP kinase. Segura-Peña D, Sekulic N, Ort S, Konrad M, Lavie A. J Biol Chem 279 33882-33889 (2004)
  3. Molecular basis for the lack of enantioselectivity of human 3-phosphoglycerate kinase. Gondeau C, Chaloin L, Lallemand P, Roy B, Périgaud C, Barman T, Varga A, Vas M, Lionne C, Arold ST. Nucleic Acids Res 36 3620-3629 (2008)
  4. Substrate specificity of vaccinia virus thymidylate kinase. Topalis D, Collinet B, Gasse C, Dugué L, Balzarini J, Pochet S, Deville-Bonne D. FEBS J 272 6254-6265 (2005)
  5. Behavior of thymidylate kinase toward monophosphate metabolites and its role in the metabolism of 1-(2'-deoxy-2'-fluoro-beta-L-arabinofuranosyl)-5-methyluracil (Clevudine) and 2',3'-didehydro-2',3'-dideoxythymidine in cells. Hu R, Li L, Degrève B, Dutschman GE, Lam W, Cheng YC. Antimicrob Agents Chemother 49 2044-2049 (2005)
  6. Mutational, inhibitory and microcalorimetric analyses of Plasmodium falciparum TMP kinase. Implications for drug discovery. Kandeel M, Ando T, Kitamura Y, Abdel-Aziz M, Kitade Y. Parasitology 136 11-25 (2009)
  7. Molecular characterization, heterologous expression and kinetic analysis of recombinant Plasmodium falciparum thymidylate kinase. Kandeel M, Kitade Y. J Biochem 144 245-250 (2008)
  8. Hydrophilically enhanced 3-carboranyl thymidine analogues (3CTAs) for boron neutron capture therapy (BNCT) of cancer. Narayanasamy S, Thirumamagal BT, Johnsamuel J, Byun Y, Al-Madhoun AS, Usova E, Cosquer GY, Yan J, Bandyopadhyaya AK, Tiwari R, Eriksson S, Tjarks W. Bioorg Med Chem 14 6886-6899 (2006)
  9. Structures of S. aureus thymidylate kinase reveal an atypical active site configuration and an intermediate conformational state upon substrate binding. Kotaka M, Dhaliwal B, Ren J, Nichols CE, Angell R, Lockyer M, Hawkins AR, Stammers DK. Protein Sci 15 774-784 (2006)
  10. Mechanism of inhibition of human immunodeficiency virus type 1 reverse transcriptase by a stavudine analogue, 4'-ethynyl stavudine triphosphate. Yang G, Wang J, Cheng Y, Dutschman GE, Tanaka H, Baba M, Cheng YC. Antimicrob Agents Chemother 52 2035-2042 (2008)
  11. Enantioselectivity of human AMP, dTMP and UMP-CMP kinases. Alexandre JA, Roy B, Topalis D, Pochet S, Périgaud C, Deville-Bonne D. Nucleic Acids Res 35 4895-4904 (2007)
  12. Mechanisms of substrate selectivity for Bacillus anthracis thymidylate kinase. Carnrot C, Wang L, Topalis D, Eriksson S. Protein Sci 17 1486-1493 (2008)
  13. Structure-based in-silico rational design of a selective peptide inhibitor for thymidine monophosphate kinase of mycobacterium tuberculosis. Kumar M, Sharma S, Srinivasan A, Singh TP, Kaur P. J Mol Model 17 1173-1182 (2011)
  14. Borononucleotides as substrates/binders for human NMP kinases: enzymatic and spectroscopic evaluation. El Amri C, Martin AR, Vasseur JJ, Smietana M. Chembiochem 13 1605-1612 (2012)
  15. Molecular cloning and characterization of Brugia malayi thymidylate kinase. Doharey PK, Suthar MK, Verma A, Kumar V, Yadav S, Balaramnavar VM, Rathaur S, Saxena AK, Siddiqi MI, Saxena JK. Acta Trop 133 83-92 (2014)
  16. Insights into the structure-function relationship of Brugia malayi thymidylate kinase (BmTMK). Doharey PK, Singh SK, Verma P, Verma A, Rathaur S, Saxena JK. Int J Biol Macromol 88 565-571 (2016)
  17. A bioluminescent method for measuring thymidylate kinase activity suitable for high-throughput screening of inhibitor. Hu CM, Chang ZF. Anal Biochem 398 269-271 (2010)
  18. A novel viral thymidylate kinase with dual kinase activity. Guevara-Hernandez E, Arvizu-Flores AA, Lugo-Sanchez ME, Velazquez-Contreras EF, Castillo-Yañez FJ, Brieba LG, Sotelo-Mundo RR. J Bioenerg Biomembr 47 431-440 (2015)
  19. Common Mechanism of Activated Catalysis in P-loop Fold Nucleoside Triphosphatases-United in Diversity. Kozlova MI, Shalaeva DN, Dibrova DV, Mulkidjanian AY. Biomolecules 12 1346 (2022)
  20. Stabilization of Active Site Dynamics Leads to Increased Activity with 3'-Azido-3'-deoxythymidine Monophosphate for F105Y Mutant Human Thymidylate Kinase. Fucci IJ, Sinha K, Rule GS. ACS Omega 5 2355-2367 (2020)